Mersana to discontinue development of one cancer treatment to focus on another [MarketWatch]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: MarketWatch
Mersana to discontinue development of one cancer treatment to focus on another Biopharmaceutical company Mersana Therapeutics Inc. MRSN, -6.50% said Friday that it will discontinue development of its XMT-1522 cancer treatment, following a strategic evaluation by the company. The stock is currently halted for news. Instead, the company will focus its resources on advancing XMT-1536. XMT-1522 was being developed with its partner, Takeda Pharmaceutical Co. Ltd. TKPHF, -0.21% 4502, +0.27% "We have made the difficult decision to terminate the further development of XMT-1522 despite a favorable emerging profile of efficacy and tolerability due to the competitive environment for HER2-targeted therapies," said Mersana Chief Executive Anna Protopapas. The company said it plans to report phase 1 trial dose escalation data in the first half of 2019. The stock has plunged 56% over the past three months, while the iShares Nasdaq Biotechnology ETF IBB, +0.14% has lost 17% and the S&P 5
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.MarketBeat
- AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]Seeking Alpha
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.MarketBeat
- Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target raised by analysts at Robert W. Baird from $1.00 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
MRSN
Earnings
- 2/28/24 - Beat
MRSN
Sec Filings
- 2/28/24 - Form 8-K
- 2/28/24 - Form 424B5
- 2/28/24 - Form POS
- MRSN's page on the SEC website